Parliamentary Search

Written question asked by Jim Shannon (Democratic Unionist Party) on Tuesday, 22 May 2018, in the House of Commons. It was due for an answer on Thursday, 24 May 2018. It was answered by Steve Brine (Conservative) on Thursday, 31 May 2018 on behalf of the Department of Health and Social Care.

Muscular Dystrophy: Medical Treatments

Question

To ask the Secretary of State for Health and Social Care, if he will take steps to ensure NICE evaluates all treatments for duchenne muscular dystrophy by the same criteria.

Answer

The National Institute for Health and Care Excellence (NICE) is the independent body responsible for the development of authoritative, evidence-based guidance for the National Health Service on whether drugs and treatments represent an effective use of resources.

Drugs for the treatment of Duchenne muscular dystrophy selected for referral to NICE are assessed using NICE’s standard methods and processes for the relevant guidance programme. Most of the treatments NICE assesses are appraised through its technology appraisal programme, but NICE also operates a separate highly specialised technology programme for the evaluation of a small number of very high cost drugs for very small patient populations. Decisions about the most appropriate programme for assessment of individual treatments, including for Duchenne muscular dystrophy, are taken following consideration against published criteria, including the size of the eligible patient population, and engagement with stakeholders.

Secondary information

Type
Written question
Reference
146853
Session
2017-19
Related items
Muscular Dystrophy: Medical Treatments
Tuesday, 3 July 2018
Written questions
House of Commons
Muscular Dystrophy: Medical Treatments
Tuesday, 3 July 2018
Written questions
House of Commons
Subjects
Medical treatments National Institute for Health and Care Excellence Muscular dystrophy
Link
View this Written question on www.parliament.uk